FDA staff cautious on AstraZeneca, Bristol diabetes drug
LONDON (Reuters) - U.S. Food and Drug Administration staff said on Tuesday they were wary about the benefits versus the risks of AstraZeneca and Brist...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/XQIee9uTiNE/story01.htm
No comments:
Post a Comment